美股异动｜Vanda Pharmaceuticals夜盘大涨超21%，晕动症药物获美国FDA批准

Core Viewpoint - Vanda Pharmaceuticals has seen a significant stock increase of over 21% following the FDA approval of its drug Nereus, which is the first treatment for exercise-induced nausea in over 40 years [1] Company Summary - Vanda Pharmaceuticals' stock price rose to $8.53 after the announcement of FDA approval for its drug Nereus [1] - The company plans to launch Nereus in the coming months [1] Industry Summary - The approval of Nereus marks a significant milestone in the pharmaceutical industry, being the first of its kind in over four decades [1]